Kramer M W, Merseburger A S, Peters I, Waalkes S, Kuczyk M A
Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625 Hannover, Deutschland.
Urologe A. 2012 Feb;51(2):217-25. doi: 10.1007/s00120-011-2713-5.
Several targeted therapies have become available for first-line (sunitinib, bevacizumab, pazopanib, temsirolimus) and second-line (sorafenib, pazopanib, everolimus) use in recent years. The superior outcomes achieved with these targeted agents have led to replacement of the formerly administered cytokines. New developments have raised the question of whether patients benefit from sequential therapies with tyrosine kinase inhibitors and/or whether combination regimes can improve clinical outcomes. This review gives an overview of the current therapeutic options for first- and second-line treatment in metastatic RCC as well as sequential and combination therapies. Adjuvant and neoadjuvant treatment options are being discussed. Furthermore, this review addresses surgical alternatives in the treatment of RCC.
近年来，已有几种靶向疗法可用于一线治疗（舒尼替尼、贝伐单抗、帕唑帕尼、替西罗莫司）和二线治疗（索拉非尼、帕唑帕尼、依维莫司）。这些靶向药物取得的卓越疗效已导致先前使用的细胞因子被取代。新的进展引发了这样一个问题，即患者是否能从酪氨酸激酶抑制剂的序贯治疗中获益，以及联合治疗方案是否能改善临床疗效。本综述概述了转移性肾细胞癌一线和二线治疗的当前治疗选择以及序贯和联合治疗。同时也讨论了辅助和新辅助治疗选择。此外，本综述还探讨了肾细胞癌治疗中的手术替代方案。
